January 1, 1999Clinical and Experimental Hypertension
Left Ventricular Hypertrophy as A Surrogate End-Point in Hypertension
Key result
Left ventricular hypertrophy presence and progression are associated with consistently higher risks of cardiovascular events in hypertension (odds ratios 1.4 to 5.4).
Why the study?
Does left ventricular hypertrophy (LVH) and its regression influence the rate of cardiovascular events in hypertension?
Population
About 20,000 subjects from 17 studies evaluating LVH presence, and 1,544 subjects from 5 studies evaluating…
Comparison
Left ventricular hypertrophy presence or… vs Absence of LVH or LVH regression
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support LVH as surrogate endpoint in hypertension; leaves open independence from BP changes.
Structured PICO
Does left ventricular hypertrophy (LVH) and its regression influence the rate of cardiovascular events in hypertension?
P
Population
About 20,000 subjects from 17 studies (7 electrocardiographic and 10 echocardiographic) evaluating LVH presence, and 1,544 subjects from 5 studies evaluating LVH progression/regression in hypertension.
I
Intervention
Left ventricular hypertrophy (LVH) presence or progression
C
Comparator
Absence of LVH or LVH regression
O
Outcome
Rate of cardiovascular events (morbid events)surrogate
Main Result
Effect estimate: OR 1.4 to 5.4
Evidence supports left ventricular hypertrophy as a surrogate end-point for cardiovascular events in hypertension, though its independence from blood pressure changes remains to be fully established.
Limitations
- The independence of the relation of LVH change to prognosis from blood pressure or other factors has not yet been fully established.
Cite This Study
Devereux et al. (1999) conducted a review in Hypertension (n=20,000). Left ventricular hypertrophy (LVH) presence or progression vs. Absence of LVH or regression was evaluated on Cardiovascular events (OR 1.4 to 5.4). Left ventricular hypertrophy presence and progression are associated with consistently higher risks of cardiovascular events in hypertension (odds ratios 1.4 to 5.4).